PROSTATE CANCER THERAPEUTICS A GLOBAL STRATEGIC BUSINESS REPORT MCP-1747 CONTENTS I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations I-1 Disclaimers I-2 Data Interpretation & Reporting Level I-2 Product Definitions and Scope of Study I-3 Hormonal Therapy I-3 Radiation Therapy I-4 Chemotherapy I-4 Surgical Procedures I-4 Other Treatment Options I-4 II. EXECUTIVE SUMMARY 1. Industry Overview II-1 A Prelude II-1 New Products to Bolster Sales of Prostate Cancer Therapeutics II-1 Key Prostate Cancer Drugs & Companies II-2 Hormone Therapies to Dominate Global Prostate Cancer Therapeutics Market II-2 Table 1: Sales of FDA Approved Prostate Cancer Hormonal Therapy Drugs in the US for 2007 (includes corresponding Graph/Chart) II-2 Select Prostate Cancer Hormonal Therapy Drugs with Year of FDA Approval II-3 Targeted Therapy - The New Frontier of Cancer Treatment II-3 Radiotherapy - Gaining Prominence II-3 Innovations in Drug Delivery: A Key Factor in Product Differentiation II-4 New Therapies Appear Over the Horizon II-4 New Generation Prostate Cancer Drugs and Their Area of Use II-4 Small Cap Companies: A Target of Private Capital Financing II-5 Drugs (that are both available and under pipeline) Developed by the Three Small-Cap Companies II-5 Minimally Invasive Devices Likely to Get Good Reception in Emerging Markets II-5 Awareness Drives European Prostate Cancer Therapeutics Market II-6 Growth Drivers II-6 Rise in Prostate Cancer Incidences & Access to Modern Therapeutics Foster Growth II-6 Table 2: New Incidences of Prostate Cancer (in '000) Worldwide for the years 2004 through 2007 (includes corresponding Graph/Chart) II-6
Copyright©2009 PR Newswire.
All rights reserved